SOURCE: Novo Nordisk A/S

June 09, 2008 08:40 ET

Transaction in Own Shares

Novo Nordisk A/S - Share repurchase programme

BAGSVAERD, DENMARK--(Marketwire - June 9, 2008) - Novo Nordisk A/S - Share repurchase programme

On 31 January 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount of up to DKK 2 billion in the period from 31 January 2008 to 6 August 2008.

Since the announcement as of 2 June 2008, the following transactions have been made under the programme:

                  Number of shares    Average      Transaction
                                   purchase price   value, DKK
Accumulated, last
 announcement            3,927,907                1,272,926,351
2 June 2008                 45,000    310.2200       13,959,900
3 June 2008                 25,000    308.9400        7,723,500
4 June 2008                 45,000    312.2000       14,049,000
6 June 2008                 75,000    318.9100       23,918,250

Accumulated, 2008        4,117,907                1,332,577,001

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 70 B shares. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 28,781,920 treasury shares, corresponding to 4.5% of the share capital. The total amount of shares in the company is 646,960,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care, In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy, Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society, With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries, Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London, Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO,' For more information, visit novonordisk,com.

Stock Exchange Announcement no 33 / 2008

Copyright © Hugin AS 2008. All rights reserved.

Contact Information

  • Further information:

    Outside North America:
    Elin K Hansen
    Tel: (+45) 4442 3450

    In North America:
    Sean Clements
    Tel: (+1) 609 514 8316

    Outside North America:
    Mads Veggerby Lausten
    Tel: (+45) 4443 7919

    Hans Rommer
    Tel: (+45) 4442 4765
    In North America:
    Christian Qvist Frandsen
    Tel: (+1) 609 919 7937